A Review of Myopia Control with Atropine

Tran, Huy; Tran, Yen H; Tran, Tuan; Jong, Monica; Coroneo, Minas T.; Sankaridurg, Padmaja

doi:10.1089/jop.2017.0144

Cited by 54 publications

(49 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Reviews covering pharmacological interventions for myopia control include one focused on primary research, 131 a Cochrane review, 56 and a more recent one focused on atropine. 132 In this article, results of relevant meta-analyses are also presented.…”

Section: Pharmacological Control Of Myopia 31 Introductionmentioning

confidence: 99%

IMI – Interventions for Controlling Myopia Onset and Progression Report

Wildsoet

Chia

Cho

et al. 2019

Invest. Ophthalmol. Vis. Sci.

Self Cite

289

275

View full text Add to dashboard Cite

Myopia has been predicted to affect approximately 50% of the world's population based on trending myopia prevalence figures. Critical to minimizing the associated adverse visual consequences of complicating ocular pathologies are interventions to prevent or delay the onset of myopia, slow its progression, and to address the problem of mechanical instability of highly myopic eyes. Although treatment approaches are growing in number, evidence of treatment efficacy is variable. This article reviews research behind such interventions under four categories: optical, pharmacological, environmental (behavioral), and surgical. In summarizing the evidence of efficacy, results from randomized controlled trials have been given most weight, although such data are very limited for some treatments. The overall conclusion of this review is that there are multiple avenues for intervention worthy of exploration in all categories, although in the case of optical, pharmacological, and behavioral interventions for preventing or slowing progression of myopia, treatment efficacy at an individual level appears quite variable, with no one treatment being 100% effective in all patients. Further research is critical to understanding the factors underlying such variability and underlying mechanisms, to guide recommendations for combined treatments. There is also room for research into novel treatment options.

show abstract

Section: Pharmacological Control Of Myopia 31 Introductionmentioning

confidence: 99%

IMI – Interventions for Controlling Myopia Onset and Progression Report

Wildsoet

Chia

Cho

et al. 2019

Invest. Ophthalmol. Vis. Sci.

Self Cite

289

275

View full text Add to dashboard Cite

show abstract

“…Several clinical methods are currently used for myopia control in children. These include atropine, 10 – 13 bifocal or multifocal soft contact lenses, 14 – 18 orthokeratology, 19 – 22 progressive addition spectacles (PALs), 23 – 27 and bifocal and prismatic bifocal spectacles. 28 Each treatment has its advantages and disadvantages, with varying levels of efficacy in slowing myopia progression.…”

Section: Introductionmentioning

confidence: 99%

Effect of Defocus Incorporated Multiple Segments Spectacle Lens Wear on Visual Function in Myopic Chinese Children

Lam

Tang

Hua

et al. 2020

Trans. Vis. Sci. Tech.

View full text Add to dashboard Cite

Purpose To compare visual function of myopic children who had worn either defocus incorporated multiple segment (DIMS) spectacle lenses or single vision (SV) spectacle lenses over two years. Methods We included 160 Chinese myopic (−1 diopter [D] to −5 D) children aged 8 to 13 years in a randomized clinical trial; they wore either DIMS lenses (DIMS; n = 79) or regular SV spectacles lenses ( n = 81) full time for 2 years. Visual function, including high-contrast visual acuity (VA) and low-contrast VA at distance and near, binocular functions, and accommodation, before, during, and after 2 years of spectacle wear were assessed when both groups wore SV corrections. Changes of visual function between the two groups and within groups were compared. Results There were no statistically significant differences in the 2-year visual function changes between DIMS and SV groups (repeated measures analysis of variance with group as factor; P > 0.05). Statistically significant improvement in the best-corrected distance high-contrast VA ( P < 0.001) and stereoacuity score ( P < 0.001) were found after DIMS lens wear over 2 years. Similar findings were observed after SV spectacle lens wear. For both the DIMS and SV groups, there were statistically significant decreases in accommodative lag, monocular and binocular amplitude of accommodation after two years ( P < 0.01), but not in the changes in distance low-contrast VA, near high-contrast VA, near low-contrast VA, or phoria. Conclusions Although changes in some visual function were shown during 2 years of DIMS lens wear, similar changes were found with SV lens wear. Wear of DIMS spectacle lenses for 2 years does not adversely affect major visual function when children return to SV corrections. Translational Relevance DIMS spectacle lenses did not cause any adverse effects on visual function.

show abstract

“…As suggested, the myopia epidemic effects the entire world [118][119][120][121][122][123][124] (also reviewed in [125]). Higher Myopia can result in severe retinal tears and detachment, choroidal degeneration, glaucoma and cataract, causing a large number of blindness in U.S. [126][127][128][129][130].…”

Section: Treatment Of Myopia By Nir Lightmentioning

confidence: 99%

Near Infrared (NIR) Light Therapy of Eye Diseases: A Review

Zhu¹,

Xiao²,

Hua³

et al. 2021

Int. J. Med. Sci.

View full text Add to dashboard Cite

Near infrared (NIR) light therapy, or photobiomodulation therapy (PBMT), has gained persistent worldwide attention in recent years as a new novel scientific approach for therapeutic applications in ophthalmology. This ongoing therapeutic adoption of NIR therapy is largely propelled by significant advances in the fields of photobiology and bioenergetics, such as the discovery of photoneuromodulation by cytochrome c oxidase and the elucidation of therapeutic biochemical processes. Upon transcranial delivery, NIR light has been shown to significantly increase cytochrome oxidase and superoxide dismutase activities which suggests its role in inducing metabolic and antioxidant beneficial effects. Furthermore, NIR light may also boost cerebral blood flow and cognitive functions in humans without adverse effects. In this review, we highlight the value of NIR therapy as a novel paradigm for treatment of visual and neurological conditions, and provide scientific evidence to support the use of NIR therapy with emphasis on molecular and cellular mechanisms in eye diseases.

show abstract

A Review of Myopia Control with Atropine

Cited by 54 publications

References 68 publications

IMI – Interventions for Controlling Myopia Onset and Progression Report

IMI – Interventions for Controlling Myopia Onset and Progression Report

Effect of Defocus Incorporated Multiple Segments Spectacle Lens Wear on Visual Function in Myopic Chinese Children

Near Infrared (NIR) Light Therapy of Eye Diseases: A Review

Contact Info

Product

Resources

About